Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren’s syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial - Bowman, SJ; Fox, R; Dörner, T (The Lancet, 2022)
et al.